RNAi Technology Market (By Product & Services: Products, Services; By Application: Drug Discovery & Development, Functional Genomics; By End-use) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2024-2033

RNAi Technology Market Size and Trends

The global RNAi technology market size was estimated at around USD 2.63 billion in 2023 and it is projected to hit around USD 10.29 billion by 2033, growing at a CAGR of 14.62% from 2024 to 2033.

Key Pointers

• North America dominated the global market with the largest market share of 39% in 2023
• Asia Pacific is estimated to expand the fastest CAGR of 16.76% from 2024 to 2033.
• By Application, the drug discovery & development segment held the largest revenue share of 69% in 2023.
• By Product & Service, the products segment generated the maximum market share in 2023.
• By Product & Service, the services segment is projected to register the highest CAGR of 16.03% from 2024 to 2033.
• By End-use, the pharmaceutical & biotechnology companies segment contributed the largest market share of 57% in 2023.

RNAi Technology Market Overview

RNA interference (RNAi) technology has revolutionized the field of genetics and molecular biology, offering a novel approach to gene silencing. This technology utilizes small interfering RNA (siRNA) and microRNA (miRNA) to regulate the expression of specific genes, making it a powerful tool for research, therapeutics, and agriculture. As the demand for targeted gene therapy and precision medicine grows, the RNAi technology market is poised for significant expansion.

RNAi Technology Market Growth Factors

The RNAi technology market is experiencing robust growth due to an advancements in genetic and molecular research have significantly enhanced the understanding of gene functions and the mechanisms of gene silencing, fostering innovation in RNAi applications. The rising prevalence of chronic diseases, such as cancer and genetic disorders, has increased the demand for targeted, effective treatments that RNAi technology can provide. Additionally, substantial investments from both government bodies and private sector companies have accelerated research and development efforts, leading to the commercialization of RNAi-based products and therapies. These factors, combined with the growing interest in precision medicine and personalized treatment approaches, are driving the expansion of the RNAi technology market.

U.S. RNAi Technology Market Size 2024 to 2033

The global RNAi technology market size was valued at USD 0.71 billion in 2023 and it is predicted to surpass around USD 2.80 billion by 2033 with a CAGR of 14.7% from 2024 to 2033.

North America accounted for the largest market share of 39% in 2023. This is attributed to the strong presence of research institutions and universities engaged in cutting-edge research in genomics, molecular biology, and biotechnology. The demand for RNAi therapeutics in research applications is driven by these institutions' exploration of technologies used in RNAi therapeutics. Moreover, government grants and funding programs provide researchers with resources to develop novel RNA technologies and therapeutic applications. These factors are anticipated to boost market growth in the region over the forecast period.

The RNAi technology market in Asia Pacific is expected to exhibit the highest CAGR of 16.76% over the forecast period. This growth is driven by a high birth rate and a high prevalence of genetic disorders, due to factors such as consanguineous marriages and founder mutations. RNA oligonucleotides and RNAi techniques are increasingly used in gene therapy applications, contributing to the region's market expansion.

RNAi Technology Market Trends:

• Increased Adoption in Therapeutics: Growing use of RNAi in developing targeted therapies for genetic disorders, cancers, and other chronic diseases.
• Advancements in Delivery Systems: Innovations in nanoparticle carriers and viral vectors to improve the safe and effective delivery of RNAi molecules to target cells.
• Expansion in Agricultural Biotechnology: Rising application of RNAi technology in crop protection, pest management, and yield improvement in agriculture.
• Focus on Personalized Medicine: Enhanced focus on precision medicine, leveraging RNAi technology to develop personalized treatment approaches based on individual genetic profiles.
• Integration with CRISPR Technology: Synergistic use of RNAi with CRISPR-Cas9 for advanced gene editing and therapeutic applications.
• Increasing Research Activities: Surge in academic and clinical research studies exploring new applications and mechanisms of RNAi technology.

RNAi Technology Market Restraints:

• Off-Target Effects: Unintended gene silencing or activation leading to potential side effects and reduced specificity in therapeutic applications.
• High Development Costs: Significant financial investment required for research, development, and clinical trials of RNAi-based therapies.
• Regulatory Hurdles: Stringent regulatory requirements and lengthy approval processes that can delay the commercialization of RNAi products.
• Intellectual Property Issues: Complex patent landscapes and intellectual property rights that can hinder innovation and create legal challenges.
• Limited Knowledge of Long-Term Effects: Insufficient understanding of the long-term safety and efficacy of RNAi therapies, posing challenges for widespread adoption.

Application Insights

The market is segmented by application into drug discovery & development, functional genomics, and others. In 2023, the drug discovery & development segment led the market with a 69% share and is projected to grow at the highest CAGR during the forecast period. RNAi technology's precise targeting and gene silencing capabilities make it a vital tool in drug discovery and development. This precision enables researchers to study gene functions and their roles in diseases more effectively, accelerating the identification and validation of new therapeutic targets. Additionally, increased investments and strategic collaborations among pharmaceutical companies to develop RNAi-based treatments, coupled with advancements in RNAi delivery techniques for enhanced efficacy, are expected to significantly drive market growth.

The functional genomics segment is anticipated to register a significant CAGR during the forecast period. This growth is driven by research efforts focused on understanding the phenotypical expressions associated with specific disease conditions. A substantial number of cancer gene therapies are developed based on functional genomic technology, which is expected to propel the segment's growth over the forecast period.

Product & Service Insights

Based on product & service, the market is divided into products (miRNA products, siRNA products, and others) and services. The products segment held the largest market share in 2023, further segmented into miRNA, siRNA, and others. miRNA and siRNA have shown considerable promise in therapeutic applications, particularly in gene silencing, crucial for addressing various illnesses such as cancer, viral infections, and hereditary conditions. Their ability to specifically target and degrade mRNA molecules enables precise molecular interventions, making them powerful tools in modern medical practices. Additionally, increasing investments are expected to advance the product portfolio.

The services segment is projected to register the highest CAGR of 16.03% over the forecast period. The complexity and technical demands of RNAi technology drive the need for specialized companies with the necessary expertise and equipment. Contract Research Organizations (CROs) and similar firms offer comprehensive RNAi services, from target identification to preclinical and clinical trial studies, facilitating the accelerated development of new drugs. This trend is expected to drive the segment's growth in the coming years.

End-use Insights

Based on end-use, the market is segmented into pharmaceutical & biotechnology companies, academic & research institutes, and CROs & CMOs. In 2023, the pharmaceutical & biotechnology companies segment dominated the market with a 57% share. This dominance is attributed to ongoing research and development efforts, the introduction of innovative therapies, and advanced pharmaceutical products. Additionally, the increasing demand for healthcare solutions and advancements in biotechnology have likely contributed to the segment's strong market position.

The CROs & CMOs segment is expected to register the highest CAGR over the forecast period. Outsourcing is becoming a strategic move for pharmaceutical and biotech firms aiming to reduce expenses and enhance operational efficiency. By entrusting specialized service providers, such as Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs), with tasks like research and production, these firms can concentrate on their core competencies. This strategy allows them to leverage the advanced expertise and technology available in the outsourcing sector, thereby propelling the growth of the segment in the foreseeable future.

RNAi Technology Market Key Companies

• Thermo Fisher Scientific, Inc.
• Merck KGaA
• Creative Biolabs
• GenScript
• Revvity
• Promega Corporation
• OriGene Technologies, Inc.
• Altogen Biosystems
• Danaher
• Bioneer Corporation

Recent Development

• In April 2024, Alnylam Pharmaceuticals shared encouraging outcomes from the KARDIA-2 Phase 2 trial of zilebesiran, an RNAi treatment targeting liver-produced angiotensinogen (AGT) for managing hypertension. This study evaluated a single subcutaneous dosage of zilebesiran in combination with standard antihypertensive drugs. The findings, unveiled at the 2024 ACC Annual Scientific Session, underscore its potential effectiveness with biannual dosing.
• In July 2023, Alnylam Pharmaceuticals, Inc. collaborated with Roche to advance and commercialize zilebesiran, an investigative RNAi medication intended for hypertension treatment.
• In July 2023, Ionis Pharmaceuticals, Inc. broadened its partnership with AstraZeneca to jointly develop and market eplontersen in the U.S. Under this agreement, AstraZeneca gained exclusive rights to market eplontersen outside the U.S., except for certain countries in Latin America.

RNAi Technology Market Segmentation:

By Product & Service

• Products
• miRNA
• siRNA
• Others
• Service

By Application

• Drug Discovery & Development
  • Neurology
  • Oncology
  • Infectious Diseases
  • Metabolic Diseases
  • Others
• Functional Genomics
• Others

By End-use

• Pharmaceutical & Biotechnology Companies
• Academic & Research Institutes
• CROs & CMOs

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa (MEA)